Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Francois must have been fired by the BOD. Just haven’t seen the filing yet. DNDODD?
Old growth is old growth, imo..
Looking forward to burning them SHORTLY.
Only watching this ticker for now. Super aggressive shorting.
The OS is 44M and this traded 96M shares the past three days and is down at these levels. Makes no sense.
FDA approval of TAEUS' De Novo application would rocket this to dollars overnight.
$NDRA
I held kgkg for three years. Didnt sell to the short man. Being rewarded today.
Yup. 2 types of people…Even though shorting has great risks
I’d rather belong to the upside. We are on the downside of markets. Do not sell to them. Bag land sucks but it’s better than making a Short man richer.
,,,,,,,IT SHOULD BE ILLEGAL TO SHORT….LIFE-SAVING CANCER AND HEALTH STOCKS LIKE NDRA
I’M JUST SAYIN.
CHECK YOUR SOUL
PAY $1,500 MRI OR ENDRA $30=GAMECHANGER
SOURCE
“ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.“
https://www.businesswire.com/news/home/20220209006120/en/ENDRA-Life-Sciences-Provides-Update-on-U.S.-Regulatory-Strategy-for-its-TAEUS®-System
,,,,,,,WELCOME!! AS A MATTER OF FACT..APRIL18TH IS LAST SUBMISSION DATE.
I WOULD THINK
THERE MIGHT BE
A PR BEFORE THEN.
(No inside information)
But you may want to give them a call. 734-335-0468
,,,,,,,I DONT TALK SHIT ALL DAY…I BACK IT UP
,,,,,,,BIG INTERNATIONAL LIVER CONFERENCE….IN A FEW WEEKS
PRETTY SURE THEY ARE PRESENTING OR HOLDING EXHIBITION
CHEERS
Don’t you read their twitter??
Just more chatter..
Why a dollar soon? I may have to add!
Ain’t gone yet, although doing quite well on NDRA, glta..
$1soon….AINT GON MISS YA….WHEN-YOUR-GONE (BYE…NOW)
A thing of beauty.. sold 1/2 (50k) .365-.373 and ecstatic.. still holding 50k..
[FLOOD THEM WITH CALLS: 734-335-0468
ATTN: FRANCOIS
WHAT YOU CAN DO NOW LONGS
Only after multiple 180 day Nasdaq extensions if not reaching $1
These are essentially gone..
Once the NDRAWs expire worthless in May, the fireworks begin. NDRA is certain to be delisted from the NASDAQ..
.29’s and below filled another 50k, now with 100k at average of .293, I guess we'll soon see how bright that was, lol..
Sure, they are instrumental in marketing securities by off loading them from institutional investors to the innocent retail investors. They have been doing that for decades. The retail guy gets it in the end as usual. The results from this firm recommending stocks is tragic..
I did fill some more @.303 (average now .306-ish)
,,,,,,,YOU’RE FUNNY! WARRANTS UP 60% AND NDRA BASICALLY NO CHANGE…JUST PLODDING ALONG. NO WORRIES HERE MATE
HOPE YOU DO GET YOUR FILL!
-CHEERS
Those selling will burn soon mark it $$$
"According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate PIPE and RD transactions cumulatively since 1998."
NDRA
And price keeps going down. Trash
HC Wainwright is a disgrace..
1 million shares traded in the first 3.5 minutes of trading
Agreed, got my buy orders in below .29
Monday will be interesting locked and loaded $$$
Average vol.6.7 million...75.4 million traded friday...Interesting..nice money flow here..
,,,,,,,LOAD’EM .88 is the trigger
Wondering if the offering filed on the 30th of last month has something to do with the drop on Friday... Watching
,,,,,,, NDRA HAS TO GET WARRANTS UP…IN—1MONTH
Now .03
TWO MAJOR PIECES OF NEWS…DUE NOW:#2
Adding limited confirmatory clinical data from a subset of ENDRA’s existing clinical evaluation sites, which is expected to be available in 2022.
"We are very encouraged with FDA’s feedback on our TAEUS System’s safety and performance data as well as their support of a De Novo pathway, which is well-suited to TAEUS’ low-to-moderate risk profile and ENDRA’s desired market claims for our novel technology. ENDRA believes it is now aligned with the FDA on the scope of the limited confirmatory clinical data, which is the primary remaining element needed for a De Novo submission. We are confident that a De Novo request is the strongest path to bring our TAEUS technology to the U.S. market. We believe this process should yield sustainable commercial advantages for our TAEUS platform
TWO MAJOR PIECES OF NEWS…DUE NOW:#1
In December 2020, ENDRA renewed its collaboration agreement with the GE Healthcare unit of the General Electric Company, extending the agreement's term by two years to December 2022.
MORE NEWS:
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on ENDRA Life Sciences, with a price target of $5.00. The company’s shares closed last Wednesday at $0.40, close to its 52-week low of $0.34.
,,,,,,,WEEEEEEE! YOU CANT CONVINCE ME….$1-$3 in 1MONTH IS NOT DOABLE
There is no loosing position $$$$
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1231
|
Created
|
10/24/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |